On February 9, 2024, Joseph Gilliam, President & COO of Glaukos Corp, executed a sale of 5,631 shares of the company. The transaction was filed with the SEC and can be viewed in detail through the provided filing.
Glaukos Corp, listed under the ticker GKOS on the NYSE, specializes in the development and commercialization of therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is known for its innovative micro-scale technologies designed to improve the lives of patients worldwide.
Over the past year, the insider has sold a total of 90,430 shares and has not made any purchases of the company's stock. This latest transaction continues the trend of insider sales for the company, with a total of 30 insider sells and no insider buys occurring over the same period.
On the day of the sale, shares of Glaukos Corp were trading at $96.14, resulting in a market capitalization of $4.700864 billion. The stock's price relative to the GuruFocus Value (GF Value) indicates that it is significantly overvalued. The GF Value, which stands at $58.49, suggests a price-to-GF-Value ratio of 1.64.
The GF Value is a proprietary valuation metric developed by GuruFocus. It is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. Additionally, it incorporates a GuruFocus adjustment factor that accounts for the company's historical returns and growth, as well as future business performance estimates provided by Morningstar analysts.
Investors and stakeholders often monitor insider transactions as they can provide insights into the insider's perspective on the value and prospects of the company. With the recent sale by Joseph Gilliam, market watchers may take note of the ongoing insider selling trend at Glaukos Corp.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
